Inventor · disambiguated record
Rajkumar Ganesan
Also filed as: GANESAN RAJKUMAR
31 granted patents·46 pending applications·39 citations·filing 2010–2025
94Inventor score
Files withJANSSEN BIOTECH INC57BOEHRINGER INGELHEIM INT9JANSSEN PHARMACEUTICA NV4GANESAN RAJKUMAR3ALECTOR LLC2
Top patents by PatentIndex Score
77 records- 0196US11236155B2Antibodies to pyroglutamate amyloid-β and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Feb 1, 2022·4 cites·23 claims
- 0293US11332541B2Multi-specific binding proteins for cancer treatmentBOEHRINGER INGELHEIM INT·Filed 2019·Granted May 17, 2022·8 cites·17 claims
- 0392US12173083B2Multi-specific binding proteins for cancer treatmentBOEHRINGER INGELHEIM INT·Filed 2022·Granted Dec 24, 2024·2 cites·18 claims
- 0491US12084501B2Proteins comprising CD3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2022·Granted Sep 10, 2024·2 cites·44 claims
- 0591US12077592B2GPRC5D chimeric antigen receptors and cells expressing the sameJANSSEN BIOTECH INC·Filed 2020·Granted Sep 3, 2024·3 cites·36 claims
- 0691US11667712B2Materials and methods for modulating t cell mediated immunityJANSSEN BIOTECH INC·Filed 2020·Granted Jun 6, 2023·2 cites·41 claims
- 0790US12180278B2Antibody targeting CD22 and CD79BJANSSEN BIOTECH INC·Filed 2022·Granted Dec 31, 2024·2 cites·29 claims
- 0889US11981932B2Materials and methods for the manufacture of pluripotent stem cellsJANSSEN BIOTECH INC·Filed 2021·Granted May 14, 2024·1 cites·12 claims
- 0986US11312785B2Antagonizing CD73 antibodyBOEHRINGER INGELHEIM INT·Filed 2019·Granted Apr 26, 2022·10 cites·45 claims
- 1081US12129310B2Materials and methods for enhanced linker targetingJANSSEN BIOTECH INC·Filed 2023·Granted Oct 29, 2024·0 cites·16 claims
- 1180US2025320286A1Antibodies to pyroglutamate amyloid-b and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2025·Application pending·0 cites
- 1279US12492256B2Methods and compositions for modulating beta chain mediated immunityJANSSEN BIOTECH INC·Filed 2024·Granted Dec 9, 2025·0 cites·28 claims
- 1379US11267880B2Anti-Sema3A antibodies and their uses for treating eye or ocular diseasesBOEHRINGER INGELHEIM INT·Filed 2020·Granted Mar 8, 2022·1 cites·26 claims
- 1479US2023250171A1Materials And Methods For Binding Siglec-3/CD33JANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1579US2023365684A1Materials And Methods For Binding Siglec-3/CD33JANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1679US2023365683A1Materials And Methods For Binding Siglec-3/CD33JANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1778US2024360421A1Materials and methods for the manufacture of pluripotent stem cellsJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1878US2024262921A1Gprc5d chimeric antigen receptors and cells expressing the sameJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1975US2025043004A1Multi-specific immune targeting molecules and uses thereofJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 2075US2025145711A1Proteins comprising cd3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 2175US2024336674A1Anti-sema3a antibodies and their uses for treating eye or ocular diseasesBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 2275US2024424130A1Compositions and methods for modulating delta gamma chain mediated immunityJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 2373US11639396B2Antibody binding to a linker peptideJANSSEN BIOTECH INC·Filed 2022·Granted May 2, 2023·0 cites·15 claims
- 2473US8435511B2Anti-hepsin antibodies and methods using sameGANESAN RAJKUMAR·Filed 2010·Granted May 7, 2013·2 cites·19 claims
- 2573US2025066474A1Antibody targeting cd22 and cd79bJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 2672US2024150464A1Materials and methods for modulating t cell mediated immunityJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 2771US8759491B2Modulators of hepatocyte growth factor activatorGANESAN RAJKUMAR·Filed 2010·Granted Jun 24, 2014·2 cites·16 claims
- 2871US2022106387A1Antibodies to pyroglutamate amyloid-b and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 2970US11965024B2Methods and compositions for modulating beta chain mediated immunityJANSSEN BIOTECH INC·Filed 2021·Granted Apr 23, 2024·0 cites·34 claims
- 3070US2024124583A1Proteins Comprising Kallikrein Related Paptidase 2 Antigen Binding Domains And Their UsesJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 3169US2024293453A1Materials and methods for binding siglec-3/cd33JANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 3268US2025043019A1TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3JANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 3367US2022144929A1Anti-sema3a antibodies and their uses for treating eye or ocular diseasesBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 3467US2022267456A1Materials and methods for targeting regulatory t cells for enhancing immune surveillanceJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 3566US2025326852A1Materials and methods for targeting regulatory t cells for enhancing immune surveillanceJANSSEN BIOTECH INC·Filed 2025·Application pending·0 cites
- 3665US12076413B2Compositions and methods for modulating delta gamma chain mediated immunityJANSSEN BIOTECH INC·Filed 2021·Granted Sep 3, 2024·0 cites·13 claims
- 3764US12264197B2Anti-Vβ17/anti-CD123 bispecific antibodiesJANSSEN BIOTECH INC·Filed 2020·Granted Apr 1, 2025·0 cites·25 claims
- 3864US2025205280A1Methods and Compositions Comprising V beta 17 Bispecific T Cell Engagers and Bioengineered Virus Specific LymphocytesJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 3964US2021130440A1Methods for producing biotherapeutics with increased stability by sequence optimizationJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 4063US2022089737A1Multi-specific immune targeting molecules and uses thereofJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 4163US2021284730A1Materials and methods for modulating delta chain mediated immunityJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 4262US2025257132A1ANTI-Vbeta17/ANTI-CD123 BISPECIFIC ANTIBODIESJANSSEN BIOTECH INC·Filed 2025·Application pending·0 cites
- 4361US12077585B2Proteins comprising kallikrein related peptidase 2 antigen binding domains and their usesJANSSEN BIOTECH INC·Filed 2020·Granted Sep 3, 2024·0 cites·96 claims
- 4460US12103977B2Trispecific antibody targeting CD79b, CD20, and CD3JANSSEN BIOTECH INC·Filed 2022·Granted Oct 1, 2024·0 cites·35 claims
- 4560US11732045B2Multi-specific binding proteins for cancer treatmentBOEHRINGER INGELHEIM INT·Filed 2020·Granted Aug 22, 2023·0 cites·20 claims
- 4660US2025092134A1Compositions and methods for the modulation of beta chain-mediated immunityJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 4759US12460001B2Proteins comprising CD3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2021·Granted Nov 4, 2025·0 cites·50 claims
- 4858US12492226B2Materials and methods for producing bioengineered virus specific lymphocytesJANSSEN BIOTECH INC·Filed 2021·Granted Dec 9, 2025·0 cites·14 claims
- 4958US12448449B2Immune targeting molecules and uses thereofJANSSEN BIOTECH INC·Filed 2021·Granted Oct 21, 2025·0 cites·5 claims
- 5058US2021355442A1Gamma delta t cells and uses thereofJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 77 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Rajkumar Ganesan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →